Navigation Links
Alexza to Announce 2010 Second Quarter Financial Results on Monday, July 26, 2010
Date:7/20/2010

MOUNTAIN VIEW, Calif., July 20 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will report results for its fiscal quarter ended June 30, 2010, on Monday, July 26, 2010 following the close of the U.S. financial markets.  The Company will host an investor conference call and live webcast to provide a company update, as well as to discuss the financial results, on Monday, July 26 at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time.  The conference call, live webcast and archived replay are open to all interested parties.

To access the conference call via the Internet, go to www.alexza.com, under the "Investor Relations" link.  Please join the call at least 15 minutes prior to the start of the call to ensure time for any software downloads that may be required.  Interested parties may also pre-register to avoid pre-call delays at https://www.theconferencingservice.com/prereg/key.process?key=P9FW8X69Y.  A replay of the call will be available for two weeks following the event.  

To access the live conference call via phone, dial 888-713-4216.  International callers may access the live call by dialing 617-213-4868.  The reference number to enter the call is 72715175.

The replay of the conference call may be accessed via the Internet, at www.alexza.com, or via phone at 888-286-8010 for domestic callers or 617-801-6888 for international callers.  The reference number for the replay of the call is 91278191.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.  Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.  The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the rapid treatment of agitation in schizophrenic or bipolar disorder patients.  Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, submitted a New Drug Application in December 2009, and has a Prescription Drug User Fee Act (PDUFA) goal date of October 11, 2010.  In February 2010, Alexza established a partnership with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize AZ-004 in the U.S. and Canada.  For more information about Alexza, the Staccato technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement

The anticipated news release and conference call will contain forward-looking statements that involve significant risks and uncertainties.  Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs.  The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements.  These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission.  Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza Pharmaceuticals Updates Staccato® Pipeline and Outlines Pipeline Development Strategy
2. Alexza Pharmaceuticals to Present at Jefferies 2010 Global Life Sciences Conference
3. Alexza Secures $25 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
4. Alexza Pharmaceuticals to Present at The Ninth Annual JMP Securities Research Conference
5. Alexza Executes $15 million Working Capital Loan with Hercules Technology Growth Capital, Inc.
6. Alexza Pharmaceuticals Files Shelf Registration Statement
7. Alexza to Announce 2010 First Quarter Financial Results on Monday, May 10, 2010
8. Alexza Reports 2009 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update
9. Alexza Pharmaceuticals Promotes Mark K. Oki to Vice President, Finance and Controller
10. Alexza Pharmaceuticals to Host 2010 Investor/Analyst Day on Thursday, February 18, 2010
11. Alexza Announces AZ-004 (Staccato(R) Loxapine) PDUFA Goal Date of October 11, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2017)... MACRA replaces the outdated sustainable growth ... reimbursement. Black Book Research crowdsource-surveyed 8,845 physician practices from ... Market for MIPS Compliance Technology is Booming ... 3 or more clinicians seek to buy Merit-Based Incentive ... magnitude of the changes, the hunt is on for ...
(Date:5/6/2017)... , May 5, 2017   Provista , a ... more than 200,000 customers, today announced Jim Cunniff ... wealth of executive and business experience to Provista, including most ... pharmacy in California . He assumed his ... "Jim is a great fit for Provista," says Jody ...
(Date:5/6/2017)... , May 5, 2017  Hill-Rom Holdings, Inc. (NYSE: ... approximately 100,000 square feet to its Welch Allyn campus. ... its commitment to bring more than 100 new jobs ... Welch Allyn has maintained a significant presence for more ... these new positions, a large portion of which will ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... , ... Rob Lowe is a sought after actor, and also serves as ... public important topics from all aspects of life, and a new segment is being ... and ankles. , Podiatry is essential to people’s overall well-being, and if viewers have ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... fluoride (PVDF) based sleep diagnostics sensors, announced today it had completed the first ... of a mix of domestic and rest of world (ROW) authorized dealers specializing ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... medical device sectors, today announced the winners of its 3rd Annual ELITE Awards. ... most influential people in the healthcare industry today. , Out of more than ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... certification body for exercise professionals, is pleased to announce the organization’s Certified Strength ... , The NCSF Certified Strength Coach (CSC) program validates the competency of qualified ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... educating patients on peri-implantitis in Las Vegas, NV, and the importance ... custom gum disease consultation and leading care for peri-implantitis, with or without a ...
Breaking Medicine News(10 mins):